# Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor

> **NCT05235438** · PHASE1 · UNKNOWN · sponsor: **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.** · enrollment: 16 (estimated)

## Conditions studied

- Oncology
- CTLA4 Haploinsufficiency

## Interventions

- **DRUG:** IMM27M

## Key facts

- **NCT ID:** NCT05235438
- **Lead sponsor:** ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-15
- **Primary completion:** 2023-08-30
- **Final completion:** 2024-08-30
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2023-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05235438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05235438, "Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT05235438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*